Mutant Amyloid Precursor Protein Differentially Alters Adipose Biology under Obesogenic and Non-Obesogenic Conditions

Oregon Health & Science University, United States of America
PLoS ONE (Impact Factor: 3.23). 08/2012; 7(8):e43193. DOI: 10.1371/journal.pone.0043193
Source: PubMed


Mutations in amyloid precursor protein (APP) have been most intensely studied in brain tissue for their link to Alzheimer's disease (AD) pathology. However, APP is highly expressed in a variety of tissues including adipose tissue, where APP is also known to exhibit increased expression in response to obesity. In our current study, we analyzed the effects of mutant APP (E693Q, D694N, K670N/M671L) expression toward multiple aspects of adipose tissue homeostasis. These data reveal significant hypoleptinemia, decreased adiposity, and reduced adipocyte size in response to mutant APP, and this was fully reversed upon high fat diet administration. Additionally, mutant APP was observed to significantly exacerbate insulin resistance, triglyceride elevations, and macrophage infiltration of adipose tissue in response to a high fat diet. Taken together, these data have significant implications for linking mutant APP expression to adipose tissue dysfunction and global changes in endocrine and metabolic function under both obesogenic and non-obesogenic conditions.

Download full-text


Available from: Le Zhang, Oct 03, 2015
24 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral amyloid angiopathy (CAA) occurs in nearly every individual with Alzheimer's disease (AD) and Down's syndrome, and is the second largest cause of intracerebral hemorrhage. Mouse models of CAA have demonstrated evidence for increased gliosis contributing to CAA pathology. Nearly two thirds of Americans are overweight or obese, with little known about the effects of obesity on the brain, although increasingly the vasculature appears to be a principle target of obesity effects on the brain. In the current study we describe for the first time whether diet induced obesity (DIO) modulates glial reactivity, amyloid levels, and inflammatory signaling in a mouse model of CAA. In these studies we identify surprisingly that DIO does not significantly increase Aβ levels, astrocyte (GFAP) or microglial (IBA-1) gliosis in the CAA mice. However, within the hippocampal gyri a localized increase in reactive microglia were increased in the CA1 and stratum oriens relative to CAA mice on a control diet. DIO was observed to selectively increase IL-6 in CAA mice, with IL-1β and TNF-α not increased in CAA mice in response to DIO. Taken together, these data show that prolonged DIO has only modest effects towards Aβ in a mouse model of CAA, but appears to elevate some localized microglial reactivity within the hippocampal gyri and selective markers of inflammatory signaling. These data are consistent with the majority of the existing literature in other models of Aβ pathology, which surprisingly show a mixed profile of DIO effects towards pathological processes in mouse models of neurodegenerative disease. The importance for considering the potential impact of ceiling effects in pathology within mouse models of Aβ pathogenesis, and the current experimental limitations for DIO in mice to fully replicate metabolic dysfunction present in human obesity, are discussed. This article is part of a Special Issue entitled: Animal Models of Disease.
    Biochimica et Biophysica Acta 01/2013; 1832(9). DOI:10.1016/j.bbadis.2013.01.002 · 4.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The global epidemic in obesity and diabetes has affected individuals in both the developing and developed world with the global death rate (63%) related to chronic diseases with 35% attributed to cardiovascular disease and stroke, 21 % to cancer and 12 % to chronic respiratory disease. The interest in connections between the global stroke epidemic, dementia and Alzheimer’s disease (AD) has increased with hypertension, smoking, diabetes, obesity, poor diet, physical inactivity, atrial fibrillation, excessive alcohol consumption, abnormal lipid profile and psychosocial stress/depression implicated in their pathogenesis. The connection between stroke and AD is possibly related to the low adiponectin and high density lipoprotein (HDL) cholesterol levels that are found in hypertensive, obese, diabetic and AD individuals. In obesity adipocyte dysfunction may be related to the down regulation of the AD gene Sirtuin 1, overexpression of the amyloid precursor protein (APP) and mitochondrial apoptosis with relevance to the renin-angiotensin system (RAS) that is associated with accelerated aging, NAFLD, stroke and AD. The unresolved finding of low plasma HDL and adiponectin in the metabolic syndrome may involve the stress hormone angiotensin II (Ang II) with vascular disturbances. Increased levels of adipocyte Ang II are possibly linked to the low plasma HDL contents in stroke and AD individuals. In obese and diabetic individuals the release of stress factors and diet control the activation of the RAS with increased levels of Ang II that are possibly implicated in the dyslipidemia associated with hypertension, cardiovascular disease, stroke and AD related dementia.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, we report a series of new 4-oxo-1,4-dihydro-quinoline-3-carboxamide derivatives as β-secretase (BACE-1) inhibitors. Supported by docking study, a small library of derivatives were designed, synthesized and biologically evaluated in vitro. The studies revealed that the most potent analog 14e (IC50 = 1.89 μM) with low cellular cytotoxicity and high predicted blood brain barrier permeability, could serve as a good structure for further modification.
    European Journal of Medicinal Chemistry 04/2014; 79C:413-421. DOI:10.1016/j.ejmech.2014.04.025 · 3.45 Impact Factor
Show more